ScoreWhy is Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 5.98% and Operating profit at -4.37% over the last 5 years
2
The company has declared negative results in Mar'2025 after 2 consecutive positive quarters
- NET PROFIT(HY) At CNY 326.44 MM has Grown at -22.55%
- INTEREST COVERAGE RATIO(Q) Lowest at 860.02
- INTEREST(Q) Highest at CNY 18.09 MM
3
With ROE of 10.58%, it has a fair valuation with a 2.58 Price to Book Value
- Over the past year, while the stock has generated a return of -24.16%, its profits have risen by 274.8% ; the PEG ratio of the company is 0.1
- At the current price, the company has a high dividend yield of 0.9
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -24.16% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
-35.05%
-0.84
30.33%
China Shanghai Composite
13.33%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
5.98%
EBIT Growth (5y)
-4.37%
EBIT to Interest (avg)
9.83
Debt to EBITDA (avg)
1.01
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.43
Tax Ratio
17.16%
Dividend Payout Ratio
19.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.32%
ROE (avg)
13.83%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
2.58
EV to EBIT
20.48
EV to EBITDA
16.26
EV to Capital Employed
2.56
EV to Sales
4.58
PEG Ratio
0.09
Dividend Yield
0.95%
ROCE (Latest)
12.52%
ROE (Latest)
10.58%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at -4.16 %
INVENTORY TURNOVER RATIO(HY)
Highest at 0.64 times
RAW MATERIAL COST(Y)
Fallen by -6.36% (YoY
CASH AND EQV(HY)
Highest at CNY 4,663.05 MM
-13What is not working for the Company
NET PROFIT(HY)
At CNY 326.44 MM has Grown at -22.55%
INTEREST COVERAGE RATIO(Q)
Lowest at 860.02
INTEREST(Q)
Highest at CNY 18.09 MM
OPERATING PROFIT(Q)
Lowest at CNY 155.6 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 16.45 %
PRE-TAX PROFIT(Q)
At CNY 139.64 MM has Fallen at -32.53%
Here's what is working for Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
Debt-Equity Ratio
Lowest at -4.16 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 0.64 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Cash and Eqv
Highest at CNY 4,663.05 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -6.36% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
Interest
At CNY 18.09 MM has Grown at 62.21%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Interest Coverage Ratio
Lowest at 860.02
in the last five periodsMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Net Profit
At CNY 326.44 MM has Grown at -22.55%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (CNY MM)
Interest
Highest at CNY 18.09 MM
in the last five periods and Increased by 62.21% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Operating Profit
Lowest at CNY 155.6 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
Operating Profit Margin
Lowest at 16.45 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
At CNY 139.64 MM has Fallen at -32.53%
over average net sales of the previous four periods of CNY 206.97 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
